BOTHELL, Wash., Aug. 6, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced financial results for the three and six months ended June 30, 2020.
Total revenue for the second quarter of 2020 was $9.9 million, a 48% increase over the second quarter of 2019. Revenue growth was driven by acquisitions completed in the second half of 2019. Revenue from biopreservation media accounted for approximately 67% of total revenue in the second quarter of 2020. Sales of BioLife's ThawSTAR®, evo® and Custom Biogenic Systems® (CBS) freezer products accounted for the balance of revenue and were in line with management's reduced expectations given the effects of COVID-19.
Mike Rice, BioLife President & CEO, commented, "We continued to advance the business during the second quarter, achieving record revenue and further adoption of our media, thaw, evo cold chain and freezer platforms. In the first half of 2020, we gained 88 new customers across the product portfolio. Significant institutional investor interest resulted in our completion of an oversubscribed public stock offering just after the close of the quarter. BioLife is very well positioned for both organic and additional acquisition driven growth."
Key Accomplishments in the Second Quarter of 2020
Financial Highlights for the Second Quarter and Six Months Ended June 30, 2020
BioLife Solutions is presenting various financial metrics under U.S. Generally Accepted Accounting Principles (GAAP) and as adjusted (non-GAAP) to reflect acquisition-related activity. A reconciliation of GAAP to non-GAAP metrics appears at the end of this news release.
REVENUE
GROSS MARGIN
OPERATING EXPENSE
OPERATING INCOME/(LOSS)
NET INCOME/(LOSS)
EARNINGS/(LOSS) PER SHARE
EBITDA
CASH
Roderick de Greef, BioLife Chief Financial Officer and Chief Operating Officer, remarked, "With the $20 million raised from Casdin Capital and an additional $86 million raised in the July follow-on offering, we are well positioned to pursue additional strategic acquisitions to strengthen our portfolio of class-defining bioproduction tools for cell and gene therapies."
2020 Financial Guidance
Due to uncertainty regarding the impact of COVID-19 on BioLife and its customers, on May 1, 2020 the Company withdrew its financial guidance for 2020.
Conference Call & Webcast
Management will discuss the Company's financial results and provide a general business update on a conference call and live webcast today at 4:30 p.m. ET (1:30 p.m. PT).
To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at http://www.biolifesolutions.com/earnings. Alternatively, you can access the live conference call by dialing 888-517-2485 with Conference ID 9675894. A webcast replay will be available approximately two hours after the call and will be archived on http://www.biolifesolutions.com/ for 90 days.
About BioLife Solutions
BioLife Solutions is a leading supplier of cell and gene therapy bioproduction tools. Our tools portfolio includes our proprietary CryoStor® freeze media and HypoThermosol® shipping and storage media, ThawSTAR® family of automated, water-free thawing products, evo® cold chain management system, and Custom Biogenic Systems® high-capacity storage freezers. For more information, please visit www.biolifesolutions.com, and follow BioLife on Twitter.
Cautions Regarding Forward Looking Statements
Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the expected financial performance of the company following the completion of its 2019 acquisitions and giving effect to the COVID-19 pandemic, the company's ability to implement its business strategy and anticipated business and operations, in particular following its 2019 acquisitions and giving effect to the COVID-19 pandemic, the company's anticipated future growth strategy, including the acquisition of synergistic cell and gene therapy manufacturing tools and services or technologies, the potential utility of and market for our products and services, potential revenue growth and market expansion, regulatory approvals and/or commercial manufacturing of our customers' products, and potential customer revenue. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding unexpected costs, charges or expenses resulting from the company's 2019 acquisitions, market adoption of the company's products (including the company's recently acquired products); the ability of the company's 2019 acquisitions to be accretive on the company's financial results; the ability of the company to implement its business strategy; uncertainty regarding third-party market projections; market volatility; competition; litigation; the impact of the COVID-19 pandemic; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
Non-GAAP Measures of Financial Performance:
To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release: adjusted gross profit and gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net income/(loss), adjusted earnings per diluted share (EPS), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release. When analyzing the Company's operating results, investors should not consider non-GAAP measures as substitutes for the comparable financial measures prepared in accordance with GAAP.
Media & Investor Relations | ||
Roderick de Greef Chief Financial and Chief Operating Officer | ||
(425) 686-6002 | ||
BIOLIFE SOLUTIONS, INC. Unaudited Condensed Statements of Operations (In thousands, except per share amounts) | ||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
(In thousands, except per share and share data) | 2020 | 2019 | 2020 | 2019 | ||||||||||||
Product Revenue | $ | 9,489 | $ | 6,701 |
$ | 21,216 |
$ |
12,471 | ||||||||
Rental revenue | 431 | ?? | 866 | ?? | ||||||||||||
Total revenue | 9,920 | 6,701 | 22,082 | 12,471 | ||||||||||||
Operating expenses | ||||||||||||||||
Cost of revenue (exclusive of intangible assets amortization) | 4,499 | 1,968 | 9,067 | 3,616 | ||||||||||||
Research and development | 1,477 | 691 | 3,140 | 1,050 | ||||||||||||
Sales and marketing | 1,366 | 945 | 2,942 | 1,782 | ||||||||||||
General and administrative | 3,278 | 2,207 | 6,413 | 4,359 | ||||||||||||
Intangible assets amortization | 706 | 104 | 1,394 | 104 | ||||||||||||
Acquisition costs | 13 | 39 | 238 | 247 | ||||||||||||
Change in fair value of contingent consideration | (1,463) | ?? | (1,526) | ?? | ||||||||||||
Total operating expenses | 9,876 | 5,954 | 21,668 | 11,158 | ||||||||||||
Operating income | 44 | 747 | 414 | 1,313 | ||||||||||||
Other income (expense), net | ||||||||||||||||
Change in fair value of warrant liability | (16,442) | 3,586 | 5,472 | (16,077) | ||||||||||||
Other income/(loss) | 18 | (81) | 42 | (145) | ||||||||||||
Total other income (expenses), net | (16,424) | 3,505 | 5,514 | (16,222) | ||||||||||||
Net income (loss) | $ | (16,380) | $ | 4,252 | $ | 5,928 | $ | (14,909) | ||||||||
Earnings (loss) per share attributable to common stockholders: | ||||||||||||||||
Basic | $ | (0.70) | $ | 0.18 | $ | 0.23 | $ | (0.80) | ||||||||
Diluted | $ | (0.70) | $ | 0.02 | $ | 0.01 | $ | (0.80) | ||||||||
Weighted average shares used to compute earnings per share attributable to common stockholders: | ||||||||||||||||
Basic | 23,292,635 | 18,819,459 | 22,151,726 | 18,734,401 | ||||||||||||
Diluted | 23,292,635 | 24,539,299 | 27,013,580 | 18,734,401 |
BIOLIFE SOLUTIONS, INC. Unaudited Condensed Balance Sheet Information (In thousands) | ||||||||
June 30, 2020 | December 31, 2019 | |||||||
Cash and cash equivalents | $ | 29,879 | $ | 6,448 | ||||
Accounts receivable, net | 4,351 | 5,345 | ||||||
Inventories | 10,890 | 10,972 | ||||||
Total current assets | 46,254 | 24,113 | ||||||
Total assets | 113,970 | 92,816 | ||||||
Accounts payable | 3,077 | 3,119 | ||||||
Total current liabilities | 7,490 | 7,669 | ||||||
Total liabilities | 8,127 | 49,362 | ||||||
Total Shareholders' equity | $ | 105,843 | $ | 43,454 |
BIOLIFE SOLUTIONS, INC. Unaudited Condensed Statement of Cash Flows Information (In thousands) | |||||||
Six Month Period Ended June 30, | |||||||
2020 | 2019 | ||||||
Cash provided by operating activities | $ | 4,407 | $ | 1,079 | |||
Cash used in investing activities | (1,683) | (12,705) | |||||
Cash provided by financing activities | 20,707 | 586 | |||||
Net increase (decrease) in cash and equivalents | $ | 23,431 | $ | (11,040) |
BIOLIFE SOLUTIONS, INC. RECONCILIATION OF GAAP GROSS PROFIT TO NON-GAAP (ADJUSTED) GROSS PROFIT (Unaudited, amounts in thousands) | ||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||
June 30, 2020 | June 30, 2019 | June 30, 2020 | June 30, 2019 | |||||||||||
GAAP GROSS PROFIT | $ | 4,834 | $ | 4,652 | $ | 11,860 | $ | 8,775 | ||||||
GAAP GROSS MARGIN | 49 | % | 69 | % | 54 | % | 70 | % | ||||||
ADJUSTMENTS TO GROSS PROFIT: | ||||||||||||||
Inventory step-up charges | 190 | 103 | 386 | 103 | ||||||||||
Intangible assets amortization | 587 | 81 | 1,155 | 81 | ||||||||||
ADJUSTED GROSS PROFIT | $ | 5,611 | $ | 4,836 | $ | 13,401 | $ | 8,959 | ||||||
ADJUSTED GROSS MARGIN | 57 | % | 72 | % | 61 | % | 72 | % | ||||||
BIOLIFE SOLUTIONS, INC. RECONCILIATION OF GAAP OPERATING EXPENSES TO NON-GAAP (ADJUSTED) OPERATING EXPENSES (Unaudited, amounts in thousands) | |||||||||||||||||
Three Months Ended | Six Months Ended | ||||||||||||||||
June 30, 2020 | June 30, 2019 | June 30, 2020 | June 30, 2019 | ||||||||||||||
GAAP OPERATNG EXPENSES | $ | 9,876 | $ | 5,954 | $ | 21,668 | $ | 11,158 | |||||||||
ADJUSTMENTS TO OPERATING EXPENSES: | |||||||||||||||||
Cost of revenue | (4,499) | (1,968) | (9,067) | (3,616) | |||||||||||||
Acquisition and integration costs | (13) | (39) | (238) | (247) | |||||||||||||
Intangible assets amortization | (706) | (104) | (1,394) | (104) | |||||||||||||
Change in fair value of contingent consideration | 1,463 | ?? | 1,526 | ?? | |||||||||||||
ADJUSTED OPERATING EXPENSES | $ | 6,121 | $ | 3,843 | $ | 12,495 | $ | 7,191 | |||||||||
BIOLIFE SOLUTIONS, INC. RECONCILIATION OF GAAP OPERATING INCOME TO NON-GAAP (ADJUSTED) OPERATING INCOME (Unaudited, amounts in thousands) | ||||||||||||
Three Months Ended | Six Months Ended | |||||||||||
June 30, 2020 | June 30, 2019 | June 30, 2020 | June 30, 2019 | |||||||||
GAAP OPEARITNG INCOME | $ | 44 | $ | 747 | $ | 414 | $ | 1,313 | ||||
ADJUSTMENTS TO OPERATING INCOME: | ||||||||||||
Inventory step-up charges | 190 | 103 | 386 | 103 | ||||||||
Acquisition and integration costs | 13 | 39 | 238 | 247 | ||||||||
Intangible assets amortization | 706 | 104 | 1,394 | 104 | ||||||||
Change in fair value of contingent consideration | (1,463) | ?? | (1,526) | ?? | ||||||||
ADJUSTED OPERATING INCOME/(LOSS) | $ | (510) | $ | 993 | $ | 906 | $ | 1,767 |
BIOLIFE SOLUTIONS, INC. RECONCILIATION OF GAAP NET INCOME TO NON-GAAP (ADJUSTED) NET INCOME (Unaudited, amounts in thousands) | ||||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||||
June 30, 2020 | June 30, 2019 | June 30, 2020 | June 30, 2019 | |||||||||||||||
GAAP NET INCOME/(LOSS) | $ | (16,380) | $ | 4,252 | $ | 5,928 | $ | (14,909) | ||||||||||
ADJUSTMENTS TO NET INCOME/(LOSS): | ||||||||||||||||||
Inventory step-up charges | 190 | 103 | 386 | 103 | ||||||||||||||
Acquisition and integration costs | 13 | 39 | 238 | 247 | ||||||||||||||
Intangible assets amortization | 706 | 104 | 1,394 | 104 | ||||||||||||||
Loss on disposal of assets | ?? | ?? | 4 | ?? | ||||||||||||||
Loss on Equity Method Investment | ?? | 217 | ?? | 448 | ||||||||||||||
Change in fair value of contingent consideration | (1,463) | ?? | (1,526) | ?? | ||||||||||||||
Change in fair value of warrant liability | 16,442 | (3,586) | (5,472) | 16,077 | ||||||||||||||
ADJUSTED NET INCOME/(LOSS) | $ | (492) | $ | 1,129 | $ | 952 | $ | 2,070 | ||||||||||
BIOLIFE SOLUTIONS, INC. RECONCILIATION OF GAAP NET INCOME PER DILUTED SHARE TO NON-GAAP (ADJUSTED) NET INCOME PER DILUTED SHARE (Unaudited, amounts in thousands) | |||||||||||||
Three Months Ended | Six Months Ended | ||||||||||||
June 30, 2020 | June 30, 2019 | June 30, 2020 | June 30, 2019 | ||||||||||
GAAP NET INCOME/(LOSS) PER SHARE - DILUTED | $ | (0.70) | $ | 0.02 | $ | 0.01 | $ | (0.80) | |||||
ADJUSTMENTS TO NET INCOME/(LOSS) PER SHARE ? DILUTED: | |||||||||||||
Inventory step-up charges | 0.01 | ?? | 0.01 | 0.01 | |||||||||
Acquisition and integration costs | ?? | ?? | 0.01 | 0.01 | |||||||||
Intangible assets amortization | 0.03 | 0.01 | 0.05 | 0.01 | |||||||||
Loss on disposal of assets | ?? | ?? | ?? | ?? | |||||||||
Loss on Equity Method Investment | ?? | 0.01 | ?? | 0.02 | |||||||||
Change in fair value of contingent consideration | (0.06) | ?? | (0.06) | ?? | |||||||||
Change in fair value of warrant liability | 0.71 | ?? | ?? | 0.86 | |||||||||
ADJUSTED NET INCOME/(LOSS) PER SHARE - DILUTED | $ | (0.01) | $ | 0.04 | $ | 0.02 | $ | 0.11 |
BIOLIFE SOLUTIONS, INC. RECONCILIATION OF GAAP NET INCOME TO NON-GAAP (ADJUSTED) EBITDA (Unaudited, amounts in thousands) | |||||||||||||||
Three Months Ended | Six Months Ended | ||||||||||||||
June 30, 2020 | June 30, 2019 | June 30, 2020 | June 30, 2019 | ||||||||||||
GAAP NET INCOME/(LOSS) | $ | (16,380) | $ | 4,252 | $ | 5,928 | $ | (14,909) | |||||||
ADJUSTMENTS: | |||||||||||||||
Interest expense/(income), net | (17) | (136) | (45) | (304) | |||||||||||
Depreciation | 560 | 110 | 973 | 209 | |||||||||||
Intangible assets amortization | 706 | 104 | 1,394 | 104 | |||||||||||
EBITDA | $ | (15,131) | $ | 4,330 | $ | 8,250 | $ | (14,900) | |||||||
OTHER ADJUSTMENTS: | |||||||||||||||
Acquisition and integration costs | 13 | 39 | 238 | 247 | |||||||||||
Inventory step-up charges | 190 | 103 | 386 | 103 | |||||||||||
Share-based compensation (non-cash) | 1,145 | 818 | 2,258 | 1,349 | |||||||||||
Loss on disposal of assets | ?? | ?? | 4 | ?? | |||||||||||
Loss from equity-method investment (SAVSU) | ?? | 217 | ?? | 448 | |||||||||||
Change in fair value of contingent consideration | (1,463) | ?? | (1,526) | ?? | |||||||||||
Change in fair value of warrant liability | 16,442 | (3,586) | (5,472) | 16,077 | |||||||||||
ADJUSTED EBITDA | $ | 1,196 | $ | 1,921 | $ | 4,138 | $ | 3,324 | |||||||
SOURCE BioLife Solutions, Inc.
These press releases may also interest you
|